Objective: The aim of this study was to estimate associations of obesity with reproductive hormone levels as women progress from premenopausal to postmenopausal status.
O besity is identified as an important modifier of reproductive hormones. In midlife women, obesity is associated with menstrual cycle alterations: anovulatory cycles ending with bleeding; menopausal symptoms including hot flashes, poor sleep, aches, and joint pain; urinary symptoms; and quality of life. 1<15 Many women experience weight gain, increases in central adiposity, and other changes in body composition around menopause, but the extent to which these changes are specific to levels or changes in reproductive hormones or to other behavioral and disease factors is complex and not clearly identified. 16, 17 Although studies have reported associations between obesity and reproductive hormones, findings are inconsistent, and mechanisms that underlie these associations are unclear. For example, some studies documented a significant effect of body mass index (BMI) on estradiol levels, whereas others did not. 15, 18 Obesity was associated with an earlier age at menopause in one study but a later age at menopause in another. 19, 20 Estradiol levels were higher in postmenopausal obese women, 21, 22 but an inverse association of BMI with estradiol and inhibin B was observed in premenopausal obese women. 11, 15, 23 Reasons for the lower levels of estradiol in premenopausal obese women are not well understood. Moreover, there is little information on the associations between obesity and reproductive hormones as midlife women progress from premenopause to postmenopause status.
In our population-based cohort, we have consistently found that body size as measured by BMI is an important mediator of hormone levels in the menopausal transition. 12<14 For example, women with higher BMI were more likely to enter the earliest transition stage, although they were less likely to reach the postmenopausal stage compared with those with lower BMI. 24 Obese women had lower levels of antimullerian hormone compared with nonobese women, although antral follicle count did not differ by body size. 14, 23 Observed racial differences in mean levels of estradiol in the menopausal transition were strongly mediated by BMI 12 However, the complex associations among BMI, menopausal stage, time, and other modifiers with hormone levels make it difficult to disentangle the independent contributions of BMI in these studies.
The objective of this study was to estimate associations between obesity and reproductive hormone levels at multiple time points as women progressed through the menopausal transition. Based on our previous observations, 12<14, 23 we hypothesized that obese women have lower estradiol levels, lower inhibin B levels, and higher follicle-stimulating hormone (FSH) levels compared with nonobese women in the earliest stages of the menopausal transition, and postmenopausal obese women have higher estradiol levels compared with nonobese women. The associations between obesity and hormones reverse in the transition stages.
METHODS

Cohort participants
All participants in the Penn Ovarian Aging cohort (N = 436) were included in this study, which was conducted during a 12-year interval from 1995 to 2007. The cohort was identified by random-digit dialing to households in Philadelphia County, PA, as described in previous reports. 14 Sampling was stratified to obtain equal numbers of African American and white women (n = 218 in each group) to determine associations of race in ovarian aging. The institutional review board of the University of Pennsylvania approved the study, and written informed consent was obtained from all participants.
At enrollment in the cohort, the participants were from 35 to 47 years old, were premenopausal with regular menstrual cycles in reference range (22-35 d) for the previous three cycles, had an intact uterus, and had at least one ovary. Exclusion criteria included current use of psychotropic or hormonal medications including hormonal contraception and hormone therapies; pregnancy or breast-feeding; serious health problems known to compromise ovarian function such as diabetes mellitus, liver disease, and breast or endometrial cancer; and alcohol or drug abuse in the past year.
During the 12-year interval, 137 participants discontinued. There were no significant differences in the variables of this study compared at baseline between the participants who continued throughout the study and the discontinuers ( Table 1) . We previously found no substantial differences between the discontinuers and active participants in a study of discontinuation in the first 5 years of the project and concluded that discontinuation was spread equally across study characteristics. 25 
Study design
Twelve assessment periods were conducted in the 12-year interval. The first 6 periods were at approximately 8-to 9-month intervals, and the remaining periods were at annual intervals with a 2-year gap between periods 10 and 11. Blood samples for the hormone assessments were obtained in each assessment period in the early follicular phase (days 1-6 of the menstrual cycle) in two consecutive menstrual cycles or 1 month apart in noncycling women (yielding a possible maximum of 24 hormone samples per participant).
The study was described to the participants as a general women's health study. At each assessment period, trained research interviewers obtained the blood samples, anthropometric measures, and all other study data in individual inperson interviews at the participants' homes. A structured interview questionnaire focused on overall health, and participants completed a set of validated self-report measures to assess health and other variables of the study.
Study variables Hormones
Estradiol and FSH were measured by radioimmunoassay in the Translational Clinical Research Center of the University of Pennsylvania using Coat-A-Count commercial kits (Diagnostic Products, Los Angeles, CA). All assays were performed in duplicate, with the means of the duplicates used in analysis. The interassay and intra-assay coefficients of variation were less than 5% for estradiol and FSH. Inhibin B was measured by an enzyme-linked immunosorbent assay using the commercial kit from Diagnostic Systems Laboratories (Webster, TX). The sensitivity of the assay was 7 pg/mL (range, 5-531 pg/mL). The interassay and intra-assay coefficients of variation (CVs) were G5% and 7.3%, respectively. For the first 10 assessment periods, Dr. Patrick Sluss, PhD, Massachusetts General Hospital, Boston, performed the inhibin B assays with a solid-phase sandwich enzyme-linked immunosorbent assay (Diagnostic Systems Laboratories, Inc, Beckman Coulter, Houston, TX) based on the use of plates coated with a monoclonal antibody specific for the >-subunit for detection. 26, 27 The limit of measurement for the assay was 15 pg/mL (CV = 20%). The assay was controlled in triplicate using samples with mean concentrations of 155.3, 316.3, and 919.3 pg/mL, with interassay CVs of 11.6%, 7.6%, and 9.7%, respectively. The reference ranges are as follows: normally cycling women, follicular phase, 64 to 146 pg/mL; normally cycling women, midcycle, 47 to 169 pg/mL; normally cycling women, luteal phase, less than 15 to 72 pg/mL; and postmenopausal women not taking hormone therapy, less than 15 pg/mL. In this report, values below the sensitivity threshold (15 pg/mL) were given the threshold value.
Anthropometric measures
Measures of height, weight, and waist-to-hip circumferences were made and recorded in duplicate at each assessment period. The average value at each period was used in analysis. Height (without shoes) was measured to the nearest 0.25 in with a vertical tape. Body weight (in light clothing) was measured to the nearest pound. Waist circumference (WC) was measured at the level of the narrowest part of the torso as seen from the anterior aspect. Hip circumference was measured at the maximal protrusion of the hips at the level of the symphysis pubis to the nearest 0.25 in. BMI (kg/m 2 ) was calculated as weight (kg) divided by the square of height (cm), using the average of the duplicate measures. Metric conversions for the analysis were computer generated. Standard cut points for three measures of adiposity were used in the analysis: BMI G25, Q25 to G30, and Q30 kg/m 2 ; WC: G80 and Q80 cm; and waist-to-hip ratio (WHR): G0.80, 0.80 to G0.84, and Q0.85.
Menopausal stage
Participants were assigned to menopausal stage at each assessment period. Menopausal stage was identified using the menstrual dates at each study visit (conducted within 6 d of bleeding) and the two previous menstrual dates reported at each visit. Other confirmatory data were provided by daily diaries that participants recorded for one menstrual cycle at each assessment period, the reported number of menstrual periods between assessments, cycle length, and number of bleeding days.
The definitions of menopausal stage were adapted from the Stages of Reproductive Aging Workshop and divided the early transition stage to better capture early transition changes. 28 We previously demonstrated significant associations between each of these stages and reproductive hormone changes. 12, 13 The five stages in this report were as follows: (1) premenopausal: regular menstrual cycles in the 22-to 35-day range; (2) late premenopausal: a change in cycle length of 7 days or more either direction from the participant's personal baseline at enrollment in the cohort and observed for at least one menstrual cycle in the study; (3) early transition: changes in cycle length of 7 days or more either direction from the participant's personal baseline at enrollment in the cohort observed for at least two consecutive menstrual cycles in the study to 60 days amenorrhea; (4) late transition: 90 days to 11 months amenorrhea; and (5) postmenopausal: 12 months or longer amenorrhea excluding hysterectomy.
Other covariates
Age at enrollment, race (African American or white), current smoking (yes, no), number of children, and age at men-arche were obtained in the study interviews and selected for this report based on their significance in previous reports and the goals of this study.
Statistical analysis
The statistical analyses used general linear mixed-effects regression models for repeated measures to estimate the associations of each anthropometric measure with each hormone. These extensions of linear regression address among-women associations, while taking into account the longitudinal data collection. We first examined the unadjusted associations of each study variable with each hormone. We then examined the anthropometric measures simultaneously with all covariates that had an adjusted association at P G 0.15 in multivariable models to estimate independent associations of the anthropometric measures with each hormone. The three-and two-way interactions among each anthropometric measure, menopausal stage, and race were included in the hormone models; each variable was adjusted for all other variables in the model. The same set of covariates was modeled for each hormone, and the final models retained all covariates and the interaction between the anthropometric measure and menopausal stage.
The hormone measures were transformed to natural log values to accommodate assumptions of the statistical models. The mean of the two hormone measurements for each participant at each assessment period was used in analysis. In cases where two hormone values were not obtained in an assessment period, the single value was used. Mean hormone values are expressed as the geometric mean (backtransformed from the natural log values) with 95% CIs.
All available data at each assessment period for the 436 participants were included in the repeated-measures models. Observations of pregnancy, breast-feeding, and hormone use were censored at the times of their occurrence. Hormone measurements taken after a participant reported hysterectomy or cancer treatment were set to missing from the time of occurrence forward. In all models, variance estimates for the statistical tests on the regression coefficients were adjusted for the repeated observations from each participant using generalized estimating equations. 29 The significance level for the within-group comparisons at each menopausal stage was lowered to P = 0.003 using the Bonferroni correction for multiple comparisons. Comparisons of baseline variables between study continuers and discontinuers used two-sample t tests or Pearson's W 2 tests of association as appropriate for the distributions of the data. All analyses were conducted using the SAS V9.13 statistical package (SAS Institute, Cary, NC). Statistical tests were two tailed, with P e 0.05 considered significant. Table 1 . The mean (SD) age was 41.4 (3.5) years, and all women were premenopausal. At assessment period 12, the mean (SD) age was 51.6 (3.4) years; three women (1%) were premenopausal, 720 Menopause, Vol. 17, No. 4, 2010 * 2010 The North American Menopause Society FREEMAN ET AL 48% were in transition, 45% were postmenopausal, and 6% had a hysterectomy. Table 2 shows the unadjusted associations of the study variables with each hormone during the study interval. The obese women had significantly lower estradiol levels compared with nonobese women on each anthropometric measure (P G 0.001). The obese women also had significantly lower inhibin B levels (P G 0.001) and higher FSH levels (P G 0.001) on average compared with nonobese women.
RESULTS
Participant characteristics at baseline are shown in
Smoking, menopausal stage, and age were significantly associated with each hormone in unadjusted analysis. Race, age at menarche, and number of children were not associated with the hormone levels in unadjusted analysis ( Table 2) .
Race and hormone levels
There were no statistically significant three-way interactions of race, BMI, and menopausal stage for estradiol, FSH, or inhibin B. A two-way interaction of race and BMI was observed only for estradiol and indicated that associations of BMI with estradiol marginally differed by race (P = 0.040).
African American women in the normal BMI group had lower estradiol levels on average compared with the white women (28.1 pg/mL [95% CI, 25.0-31.5] and 33.7 pg/mL [95% CI, 30.3-35.3], respectively.) There was no significant interaction of race and BMI for FSH or inhibin B, and there were no significant interactions of race with the other anthropometric measures.
BMI and hormone levels
We estimated the association of BMI with each hormone in a multivariable model that included menopausal stage, smoking, age, race, and the interactions of BMI with menopausal stage and race. The significant interaction (P G 0.001) depicted in Fig. 1A indicated that the associations of BMI with estradiol differed by menopausal stage. In the premenopausal stage, estradiol levels were significantly lower in the obese and the overweight groups compared with the normal BMI group (obese: 32 Interaction between BMI and menopausal stage for estradiol (P G 0.001) (A), FSH (P = 0.008) (B), and inhibin B (P = 0.004) (C) from the full multivariable models. Hormone values are the geometric means with 95% CI, estimated from multivariable models that adjusted for race, age, and smoking and within-women correlation using repeated measurements. The reduced significance level with the Bonferroni correction for within-group comparisons at each menopausal stage is P = 0.003. N = 436 with 3,581 observations for estradiol, 3,578 observations for FSH, and 3,051 observations for inhibin B. BMI, body mass index; FSH, follicle-stimulating hormone. normal weight: 59.3 mIU/mL [95% CI, 50.6-69.5]; interaction P = 0.008, obese vs normal P G 0.001, overweight vs normal P = 0.007). Figure 1C indicates that the associations of BMI with inhibin B levels differed by menopausal stage, as indicated by the significant interaction (P = 0.004). Inhibin B levels were significantly lower in the obese and overweight groups at the premenopausal and late premenopausal stages but switched in the late transition stage when the normal-weight BMI group had the lowest inhibin B levels and the obese group had the highest inhibin B levels (interaction P = 0.004, shown in Fig. 1C ). Postmenopause inhibin B levels were below the limit of detection for many women regardless of weight status. Figure 2 shows the results for WC, a measure of central adiposity, which paralleled the BMI results. The association of WC with estradiol differed by menopausal stage, as indicated by the significant interaction (P G 0.001). Premenopause estradiol levels on average were significantly lower in the obese (high) WC group compared with the low WC group (P G 0.001), whereas postmenopause estradiol levels were significantly higher in the obese WC group compared with the low WC group (P = 0.002).
WC and hormone levels
FSH levels in the WC groups diverged at the late transition stage (interaction P G 0.001). Postmenopause, the obese group had the lowest FSH levels (47.2 mIU/mL; 95% CI, 42.4-52.5) compared with the nonobese group (61.1; 95% CI, 51.8-72.1, P = 0.005).
Premenopausal inhibin B levels were significantly lower on average in the obese (high) WC group compared with the nonobese group (60.4 ng/mL [95% CI, 56.8-64.3] and 72.5 ng/mL [95% CI, 67.4-78.0], respectively, P G 0.001). Postmenopause, the mean inhibin B levels approached the limit of detection; there was no significant interaction.
WHR and hormone levels
The results for WHR, a measure of visceral fat, were consistent with the BMI and WC measures. Premenopausal estradiol levels were significantly lower in the obese (high) WHR group compared with the low WHR group (37.9 pg/mL [95% CI, 35.5-40.3] and WHR 37.8 pg/mL [95% CI, 31.4-35.9], respectively, P = 0.003). The estradiol associations reversed in the late transition; the postmenopausal obese group had the highest estradiol levels, and the lowest WHR group had the lowest estradiol levels, but differences did not reach statistical significance. The interaction of WHR and menopausal stage did not reach significance (P = 0.096).
The association between WHR and FSH levels differed by menopausal stage (interaction P = 0.005). Postmenopause, the obese (high) WHR group had the lowest FSH levels and the low WHR group had the highest FSH levels (46.7 mIU/mL [95% CI, 40.9-53.3] and 58.6 [95% CI, 50.9-67.4], respectively, P = 0.009).
The association between WHR and inhibin B levels differed in the premenopausal women. Premenopausal inhibin B levels were significantly lower in the obese (high WHR) group compared with the low WHR group (P = 0.003) and were also higher in the overweight group compared with the normal WHR group (59.3 ng/mL [95% CI, 54.5-64.6], 63.2 ng/mL [95% CI, 58.9-67.8], and 68.9 ng/mL [95% CI, 64.4-73.7], respectively). Postmenopause, most women had nondetectable inhibin B levels; there was no significant interaction.
DISCUSSION
This study examined associations between obesity and reproductive hormones as women progressed from premenopause to postmenopause status. By examining women at multiple time points during a 12-year period, the findings provide novel information about these associations during OBESITY AND REPRODUCTIVE HORMONE LEVELS the menopausal transition. Obese premenopausal women had significantly lower estradiol and inhibin levels than did nonobese premenopausal women. The associations between obesity and hormones reversed in the transition stages, and after menopause, obese women had significantly higher estradiol levels compared with nonobese women.
The results also clearly indicate that obesity is associated with hormone levels independent of other factors known to influence reproductive hormones such as age, race, and smoking status. We suspect that the change in association between estradiol levels and menopause status is principally related to the source of estrogen production. The positive association of BMI and estradiol in postmenopausal obese women is consistent with the well-recognized changes in estrogen metabolism that occur with ovarian senescence, when the contribution of estradiol from fat becomes dominant and obese women have higher estradiol levels than do nonobese women. However, less is known about the inverse association of BMI with estradiol and the lower levels of inhibin B in premenopausal obese women. 11, 13, 21 Although these results confirm and further extend previous observations of a negative association between estradiol and BMI in premenopausal women, 15, 21, 23 the mechanisms for this association remain unclear. Possibly, the low levels of sex hormoneYbinding globulin in obese premenopausal women, which are positively correlated with estradiol levels, 30, 31 result in greater clearance and, consequently, lower levels of estradiol. After menopause, when the ovarian contribution of estrogen is negligible, the higher levels of estrogen in obese women may be attributed to the contribution from the conversion of androgens to estrogens by aromatase in adipose tissue.
It is hypothesized that the association between obesity and hormones is related to insulin resistance or to other adipose-derived substances such as adiponectin or leptin. 32, 33 However, measures of insulin sensitivity did not relate to reproductive hormones in obese women in the menopausal transition, suggesting that BMI may influence reproductive hormones apart from its relationship with the metabolic syndrome. 11 It is possible that obesity has a negative effect on granulosa cell function and, therefore, decreases inhibin B levels. This would explain the negative association between inhibin B and BMI, which becomes less evident as follicles become depleted with advancing menopausal stage. Given that inhibin is a direct product of the ovary, it should become undetectable regardless of BMI in postmenopausal women, as we observed. The interaction between BMI and menopausal stage indicates that the decline of inhibin B differs between obese and thin women, but this may simply be that the thin women have higher inhibin B levels at the premenopausal baseline.
The inverse associations of inhibin B and estradiol with BMI in premenopausal women suggest that obese women may experience an earlier decline in ovarian reserve compared with nonobese women. However, the FSH levels do not support this hypothesis. Increased body size in this cohort and other studies is associated with low FSH levels, and FSH levels are similar in obese and nonobese women as they enter the menopausal transition. 12, 15, 21 Furthermore, we conducted a study of effects of body size on ovarian reserve and found no difference in antral follicle count by body size, although antimullerian hormone levels were lower in obese compared with nonobese women, consistent with the observations of inhibin B in the present report. 23 Race does not seem to be a strong factor in the differential hormone levels of this study after adjusting for body size. Only estradiol had a racial association with menopause status, and this was observed only in the premenopausal stage, when the nonobese African American women had significantly lower estradiol levels compared with the white women. There was no racial difference in the subsequent menopausal transition stages in the adjusted models. We know of no explanation for the lower estradiol levels in premenopausal African American women but speculate that differences in body composition and lean body mass may be contributing factors.
The study included three measures of adiposity because there is lack of agreement on the measure that best identifies relationships between body fat and hormone dynamics. From diverse reports, it seems that BMI is a strong measure of associations with reproductive hormones but that the strength of the measurement may vary with the specific objectives of the study and characteristics of the sample. In the present study, BMI had the strongest associations with reproductive hormones; WC as a global measure of central fat paralleled the BMI results; WHR, a measure of body shape and abdominal visceral fat, was a weaker measure, particularly after adjustment in multivariable analyses. These findings are consistent with the Women_s Ischeme Syndrome Evaluation (WISE) study, in which BMI and WC were significantly associated with estrogens in postmenopausal women, and the highest estradiol levels were observed in obese women with large waists. 34 Abdominal adiposity measured by CT scan was highly correlated with BMI, subcutaneous adiposity, and visceral adiposity in the Study of Women_s Health Across the Nation (SWAN) study. 35 Another study of associations between obesity and reproductive hormones used BMI and dualenergy x-ray absorptiometry scans but determined that the scans provided no further information than that obtained with BMI. 36 In contrast, studies of older people that examined adiposity and related risk factors found that WC and WHR but not BMI were predictors of cardiovascular and mortality risks. 37, 38 Several limitations are considered. The hormones measurement was done in the early follicular phase, which is believed to be most reliable, but does not address the dynamics of the full menstrual cycle. Because estrone levels are expected to be higher in obese women due to the peripheral conversion of androgen, our findings might be even stronger if we measured estrone in addition to estradiol. Obesity may be associated with other hormones such as testosterone or sex hormoneY binding globulin that were not included in this study. 36, 39 It is possible that results could be biased by discontinuation in the cohort during the 12-year follow-up period, although this is not supported by the evidence, which showed that missing data were missing at random and were assumed to be nondifferential with respect to the outcome. The study evaluated generally healthy African American and white women with no current hormone use and may not be generalizable to all perimenopausal women.
The strengths of this study include multiple assessments over a long time period in a population-based cohort, a clearly defined premenopausal baseline from which the women progressed through the menopausal transition, with concomitant hormone and anthropometric measures.
CONCLUSIONS
The findings clearly indicate that obesity is an important factor in hormone changes of the menopausal transition independent of age, race, and smoking. The novel findings are important for better understanding the physiologic changes that occur during the menopausal transition. The findings also indicate that the effects of obesity should be considered when interpreting hormone levels of midlife women, although it is important to recognize that group differences in mean hormone levels have limited clinical utility for individual women. In menopause management, it is well recognized that the large variability in hormone levels between and within women constrains the information that can be gained from individual hormone measures, but that increased understanding of the physiologic changes is an important tool for guiding symptom management.
